Runben Biotechnology Co Ltd Ordinary Shares - Class A
Runben Biotechnology Co., Ltd. engages in the research, production, and sale of mosquito repellent products, baby care products, and essential oil products. The company sells its products through online channels. Runben Biotechnology Co., Ltd. was founded in 1993 and is based in Guangzhou, China.Runben Biotechnology Co., Ltd. operates as a subsidiary of Guangzhou Zhuofan Investment Holding Co., L… Read more
Market Cap & Net Worth: Runben Biotechnology Co Ltd Ordinary Shares - Class A (603193)
Runben Biotechnology Co Ltd Ordinary Shares - Class A (SHG:603193) has a market capitalization of $1.23 Billion (CN¥9.05 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #13965 globally and #3633 in its home market, demonstrating a 1.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Runben Biotechnology Co Ltd Ordinary Shares - Class A's stock price CN¥22.38 by its total outstanding shares 404593314 (404.59 Million).
Runben Biotechnology Co Ltd Ordinary Shares - Class A Market Cap History: 2025 to 2026
Runben Biotechnology Co Ltd Ordinary Shares - Class A's market capitalization history from 2025 to 2026. Data shows growth from $1.34 Billion to $1.23 Billion (0.00% CAGR).
Runben Biotechnology Co Ltd Ordinary Shares - Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Runben Biotechnology Co Ltd Ordinary Shares - Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 603193 by Market Capitalization
Companies near Runben Biotechnology Co Ltd Ordinary Shares - Class A in the global market cap rankings as of March 18, 2026.
Key companies related to Runben Biotechnology Co Ltd Ordinary Shares - Class A by market ranking:
- Procter & Gamble Company (NYSE:PG): Ranked #35 globally with a market cap of $351.41 Billion USD.
- Unilever PLC (PINK:UNLYF): Ranked #141 globally with a market cap of $131.81 Billion USD.
- UNILEVER PLC LS -,035 (XETRA:UNV0): Ranked #147 globally with a market cap of $126.11 Billion USD ( €122.86 Billion EUR).
- L'Oréal S.A (PINK:LRLCF): Ranked #215 globally with a market cap of $94.58 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #35 | Procter & Gamble Company | NYSE:PG | $351.41 Billion | $151.48 |
| #141 | Unilever PLC | PINK:UNLYF | $131.81 Billion | $60.96 |
| #147 | UNILEVER PLC LS -,035 | XETRA:UNV0 | $126.11 Billion | €56.81 |
| #215 | L'Oréal S.A | PINK:LRLCF | $94.58 Billion | $368.10 |
Runben Biotechnology Co Ltd Ordinary Shares - Class A Historical Marketcap From 2025 to 2026
Between 2025 and today, Runben Biotechnology Co Ltd Ordinary Shares - Class A's market cap moved from $1.34 Billion to $ 1.23 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.23 Billion | -7.64% |
| 2025 | CN¥1.34 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Runben Biotechnology Co Ltd Ordinary Shares - Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.23 Billion USD |
| MoneyControl | $1.23 Billion USD |
| MarketWatch | $1.23 Billion USD |
| marketcap.company | $1.23 Billion USD |
| Reuters | $1.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.